Obesity and psychotropics
- PMID: 22070396
- PMCID: PMC6493485
- DOI: 10.1111/j.1755-5949.2011.00232.x
Obesity and psychotropics
Abstract
Weight gain is on the rise in the United States as is the diagnosis and treatment of mental disorders. These two phenomena are distinctly separate but tend to overlap in that most psychotropic agents approved for use in the United States are associated with the potential to induce weight gain. Metabolic disorders such as diabetes, hypercholesterolemia, and hypertension are also on the rise and often associated with weight gain and clearly associated with certain psychotropic medications. This article serves to provide a succinct review regarding the epidemiology, etiology, and treatment options for psychotropic-induced obesity.
© 2011 Blackwell Publishing Ltd.
Conflict of interest statement
The authors have no conflict of interest.
References
- 
    - David BA, Janet LM, Moonseong H. Antipsychotic‐induced weight gain: A comprehensive research synthesis. Am J Psych 1999;156:1686–1696. - PubMed
 
- 
    - Masand PS. Weight gain associated with psychotropic drugs. Expert Opin Pharmacother 2000;1:377–373. - PubMed
 
- 
    - Pijl H, Meinders AE. Body weight changes as an adverse effect of drug treatment. Mechanisms and management. Drug Saf 1996;14:329–342. - PubMed
 
- 
    - Nasrallah H. A review of the effect of atypical antipsychotics in weight. Psychoneuroendocrinology.2003;28:83–99. - PubMed
 
- 
    - Corman CL, Leung NM, Guberman AH. Weight gain in epileptic patients during treatment with valproic acid: A retrospective study. Canadian J Neuro Sci 1997;24:240–244. - PubMed
 
Publication types
MeSH terms
Substances
LinkOut - more resources
- Full Text Sources
- Medical
 
        